Ostatní
Návod 
BioNTech SE
BNTX
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
25.3B
Obrat
3B
Zisk
-1B
Aktiva
22B
Dluh
0B
ROE
0%
ROA
0%
PE
-19
PS
8
Cena 1R
81-127
⌀ Cena
102.93
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
09-03-2026
Poslední dividenda
Profil
BioNTech SE, biotechnologická společnost, vyvíjí a komercializuje imunoterapie pro rakovinu a další infekční nemoci. Společnost vyvíjí přípravek FixVac, včetně BNT111, který je součástí klinické studie fáze II zaměřené na pokročilý melanom; BNT112, který je součástí klinické studie fáze I/IIa zaměřené na karcinom prostaty; BNT113, který je součástí klinické studie fáze II zaměřené na léčbu karcinomu hlavy a krku; BNT114, který je součástí klinické studie fáze I zaměřené na trojitě negativní karcinom prsu; BNT115, který je součástí klinické studie fáze I zaměřené na karcinom ovaria, a BNT116, preklinického přípravku určeného pro nemalobuněčný karcinom plic. Vyvíjí také imunoterapie specifické pro antigeny, jako je Autogene cevumeran (BNT122), který je v klinické studii fáze II na melanom první linie, stejně jako v klinické studii fáze 1a/1b na léčbu mnohočetných solidních nádorů; mRNA intratumorální imunoterapii zahrnující SAR441000, která je ve fázi I klinické studie na solidní nádory; a BNT141 a BNT142, které jsou v klinické studii fáze I na léčbu mnohočetných solidních nádorů. Kromě toho společnost vyvíjí RiboCytokiny, které zahrnují BNT151, BNT152 a BNT153 pro léčbu solidních nádorů; imunoterapie chimerických antigenních receptorů T buněk, jako je BNT211 pro léčbu mnohočetných solidních nádorů a BNT221 pro léčbu jiných nádorů; a kontrolní imunomodulátory sestávající z GEN1046 a GEN1042, které jsou v klinické studii fáze I/II pro léčbu solidních nádorů. Dále se vyvíjí BNT321, monoklonální protilátka IgG1 v klinické studii fáze II na rakovinu slinivky břišní; BNT411, kandidát na malý molekulární imunomodulátor pro solidní tumory; profylaktická vakcína proti COVID-19 a chřipce; a imunoterapie infekčního onemocnění a terapie náhrady proteinů vzácných onemocnění. Společnost spolupracuje se společnostmi Genentech, Inc., Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd. a Regeneron Pharmaceuticals, Inc. BioNTech SE, která byla založena v roce 2008 a má sídlo v Mohuči, Německo.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
6772
Založení
2019-10-10
Podobné společnosti
$ 104.50
- $ 1.48
$ 29.05
+ $ 0.39
$ 450.61
+ $ 1.70
$ 24.30
+ $ 0.33
$ 54.68
- $ 0.32
$ 205.56
+ $ 5.99
$ 28.20
+ $ 0.03
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 2,861.4 | 2,756.6 | 2,751.1 | 3,819.0 | 17,310.6 | 18,976.7 | 482.3 | 108.6 | 127.6 | 61.6 | |
| Cost of Revenues | 638.7 | 616.5 | 541.3 | 599.8 | 4,532.0 | 3,860.7 | 704.4 | 243.8 | 156.7 | 94.8 | |
| Gross Profit | 2,222.7 | 2,140.2 | 2,209.8 | 3,219.2 | 12,778.6 | 15,116.0 | -222.0 | -135.2 | -29.2 | -33.2 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 898.9 | 1,518.9 | 260.8 | 182.8 | 1,190.0 | 1,244.8 | 128.7 | 187.6 | 1,479.0 | 895.3 | |
| Cost of Revenues | 330.2 | 148.3 | 76.4 | 83.8 | 243.5 | 178.9 | 59.8 | 59.1 | 179.1 | 659.7 | |
| Gross Profit | 568.7 | 1,370.6 | 184.4 | 99.0 | 946.5 | 1,065.9 | 68.9 | 128.5 | 1,299.9 | 235.6 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 1,783.1 | 116.0 | 102.7 | 645.0 | 226.5 | 143.0 | 85.5 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 557.7 | 544.2 | 328.9 | 108.6 | 43.4 | 27.1 | 29.5 | |
| Depreciation & Amortization | 381.3 | 367.7 | 298.0 | 183.4 | 453.6 | -313.1 | 40.3 | 35.4 | 22.0 | 10.5 | |
| Total Operating Expenses | 3,535.4 | 2,764.0 | 3,524.1 | 2,528.8 | 135.9 | 200.1 | -139.6 | 46.3 | 24.7 | 28.1 | |
| Operating Income | -1,312.7 | -623.9 | -1,314.3 | 690.4 | 12,642.7 | 15,283.8 | -82.4 | -181.5 | -53.9 | -61.3 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 577.8 | 512.4 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 149.4 | 150.8 | ||
| Depreciation & Amortization | 163.3 | 124.2 | 51.0 | 42.8 | 165.4 | 44.4 | 49.9 | 38.3 | 76.8 | 42.5 | ||
| Total Operating Expenses | 799.3 | 1,417.5 | 685.5 | 633.1 | 797.9 | 1,055.4 | 1,035.1 | 635.7 | 701.9 | 153.7 | ||
| Operating Income | -230.6 | -46.9 | -501.1 | -534.1 | 148.6 | 10.5 | -966.2 | -507.2 | 526.2 | 73.1 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 260.1 | 252.2 | 0.0 | 357.6 | 330.3 | 1.5 | 1.6 | 1.8 | 2.0 | 2.1 | |
| Interest Expense | 16.4 | 13.6 | 13.2 | 7.9 | 18.9 | 5.4 | 64.9 | 1.7 | 1.7 | 0.7 | |
| Other Expense | 264.0 | -385.5 | 636.6 | 495.7 | 311.4 | -237.4 | -63.4 | 2.1 | 6.0 | -26.0 | |
| IBT | -1,048.7 | -1,009.3 | -677.7 | 1,186.1 | 12,954.1 | 15,046.4 | -145.8 | -179.4 | -47.7 | -85.9 | |
| Income Tax Expense | 84.6 | 81.9 | -12.4 | 255.8 | 3,519.7 | 4,753.9 | -161.0 | -0.3 | 0.6 | 0.0 | |
| Net Income | -1,133.2 | -1,091.3 | -665.3 | 930.3 | 9,434.4 | 10,292.5 | 15.2 | -179.2 | -48.0 | -85.7 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 260.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 168.2 | 181.9 | 120.4 | 92.5 | ||
| Interest Expense | 6.4 | 0.4 | 3.3 | 6.2 | 0.0 | 5.2 | 7.3 | 4.7 | 18.9 | 2.0 | ||
| Other Expense | 5.3 | 71.6 | 98.4 | 88.7 | 152.6 | 148.2 | 160.4 | 175.4 | 137.0 | 154.3 | ||
| IBT | -225.3 | 24.7 | -402.7 | -445.4 | 301.2 | 158.7 | -805.8 | -331.8 | 663.2 | 227.4 | ||
| Income Tax Expense | 76.9 | 53.4 | -16.1 | -29.6 | 41.7 | -39.4 | 2.0 | -16.7 | 205.3 | 66.8 | ||
| Net Income | -302.1 | -28.7 | -386.6 | -415.8 | 259.5 | 198.1 | -807.8 | -315.1 | 457.9 | 160.6 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $3.83 | $38.78 | $42.18 | $0.06 | $-0.85 | $-0.21 | $-0.38 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $3.83 | $37.77 | $39.63 | $0.06 | $-0.85 | $-0.21 | $-0.38 | |
| Shares Outstanding | 245.2 | 241.7 | 240.4 | 242.9 | 243.3 | 244.0 | 253.3 | 211.5 | 226.9 | 226.9 | |
| Diluted Shares Outstanding | 245.2 | 241.7 | 240.4 | 242.7 | 249.8 | 259.7 | 253.3 | 211.5 | 226.9 | 226.9 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.88 | $0.69 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.84 | $0.69 | ||
| Shares Outstanding | 245.2 | 239.2 | 241.6 | 240.3 | 240.3 | 239.7 | 237.7 | 240.5 | 237.7 | 239.7 | ||
| Diluted Shares Outstanding | 245.2 | 239.2 | 241.6 | 240.3 | 240.3 | 244.6 | 237.7 | 240.5 | 241.9 | 239.7 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 10,382.8 | 9,761.9 | 11,663.7 | 13,875.1 | 1,692.7 | 1,210.2 | 519.1 | 411.5 | 172.1 | 303.7 | |
| Short Term Investments | 6,919.0 | 7,021.7 | 4,885.3 | 189.4 | 381.6 | 137.2 | 1.7 | 0.3 | 0.2 | 1.5 | |
| Total Cash & ST Investments | 10,382.8 | 16,783.6 | 16,549.0 | 14,064.5 | 2,074.3 | 1,347.4 | 520.8 | 411.8 | 172.4 | 305.2 | |
| Accounts Receivable | 286.7 | 1,523.9 | 2,160.6 | 7,146.0 | 12,382.1 | 166.4 | 20.2 | 28.4 | 9.1 | 6.0 | |
| Inventory | 340.3 | 283.4 | 357.7 | 439.6 | 502.5 | 64.1 | 11.7 | 5.8 | 3.9 | 3.3 | |
| Other Current Assets | 7,282.6 | 212.6 | 460.0 | 271.9 | 64.9 | 61.0 | 1.2 | 0.4 | 1.6 | 1.7 | |
| Total Current Assets | 18,292.4 | 18,803.5 | 19,527.3 | 21,922.0 | 15,072.3 | 1,666.9 | 560.2 | 449.0 | 189.6 | 318.1 |
| Current Assets | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 10,269.5 | 10,184.9 | 9,761.9 | 9,624.6 | 10,382.8 | 8,984.9 | 11,663.7 | 13,495.8 | 14,166.6 | 12,143.9 | |
| Short Term Investments | 3,767.2 | 3,924.9 | 7,021.7 | 7,100.6 | 6,919.0 | 0.0 | 4,885.3 | 2,253.3 | 1,390.7 | 358.0 | |
| Total Cash & ST Investments | 14,036.7 | 14,109.8 | 16,783.6 | 16,748.0 | 17,295.7 | 8,984.9 | 16,549.0 | 15,749.1 | 15,557.3 | 12,501.9 | |
| Accounts Receivable | 1,446.7 | 1,027.0 | 1,523.9 | 1,200.8 | 79.7 | 1,927.0 | 2,160.6 | 2,008.8 | 2,663.8 | 6,456.2 | |
| Inventory | 230.7 | 254.4 | 283.4 | 303.8 | 340.3 | 345.7 | 357.7 | 415.7 | 448.9 | 424.1 | |
| Other Current Assets | 215.0 | 234.3 | 212.6 | 277.4 | 566.1 | 335.2 | 460.0 | 575.5 | 543.9 | 703.9 | |
| Total Current Assets | 15,929.1 | 15,625.5 | 18,803.5 | 18,530.0 | 18,281.6 | 18,291.0 | 19,527.3 | 18,749.1 | 19,213.9 | 20,086.1 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 1,125.7 | 1,183.4 | 971.6 | 821.1 | 520.4 | 326.0 | 148.1 | 116.0 | 101.5 | 60.5 | |
| Goodwill | 372.4 | 380.6 | 362.5 | 61.2 | 57.8 | 53.7 | 3.0 | 0.5 | 0.5 | 0.5 | |
| Intangible Assets | 862.3 | 790.4 | 781.7 | 158.5 | 144.6 | 109.8 | 86.5 | 87.5 | 83.0 | 10.7 | |
| Long-Term Investments | 1,386.9 | 1,254.0 | 1,176.1 | 80.2 | 21.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | |
| Other Long-Term Assets | 109.0 | 36.1 | 187.1 | 6.5 | 0.8 | 1.0 | 0.0 | 0.0 | 0.0 | 0.1 | |
| Total Long-Term Assets | 3,958.6 | 3,726.2 | 3,479.0 | 1,357.1 | 758.5 | 651.7 | 237.5 | 204.0 | 185.1 | 71.8 | |
| Total Assets | 22,251.0 | 22,529.7 | 23,006.3 | 23,279.1 | 15,830.8 | 2,318.6 | 797.6 | 653.0 | 374.7 | 390.0 |
| Long-Term Assets | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 1,242.1 | 1,268.0 | 1,183.4 | 1,162.1 | 1,125.7 | 1,031.9 | 971.6 | 925.9 | 894.0 | 847.6 | |
| Goodwill | 364.1 | 375.9 | 380.6 | 374.9 | 372.4 | 368.7 | 362.5 | 365.6 | 0.0 | 0.0 | |
| Intangible Assets | 1,487.0 | 1,511.2 | 790.4 | 876.0 | 862.3 | 821.7 | 804.1 | 665.5 | 501.4 | 378.6 | |
| Long-Term Investments | 2,504.8 | 2,285.8 | 1,254.0 | 1,335.4 | 1,386.1 | 1,588.7 | 1,176.1 | 1,292.7 | 1,374.3 | 516.8 | |
| Other Long-Term Assets | 32.7 | 30.5 | 36.1 | 85.0 | 126.3 | 84.4 | 83.4 | 0.3 | 2.5 | 4.4 | |
| Total Long-Term Assets | 5,708.5 | 5,556.9 | 3,726.2 | 3,924.3 | 3,956.3 | 3,986.4 | 3,479.0 | 3,458.1 | 3,011.7 | 1,992.9 | |
| Total Assets | 21,637.6 | 21,182.4 | 22,529.7 | 22,454.3 | 22,237.9 | 22,277.4 | 23,006.3 | 22,207.2 | 22,225.6 | 22,079.0 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 882.0 | 426.7 | 354.0 | 204.1 | 160.0 | 102.3 | 20.5 | 41.7 | 52.5 | 6.2 | |
| Short-Term Debt | 35.3 | 39.5 | 0.0 | 36.0 | 129.9 | 9.1 | 7.6 | 6.2 | 19.4 | 3.0 | |
| Other Current Liabilities | 1,035.4 | 1,757.6 | 1,191.0 | 2,633.4 | 3,002.6 | 103.1 | 16.4 | 12.1 | 9.3 | 13.9 | |
| Current Liabilities | 2,427.3 | 2,523.2 | 2,070.5 | 2,950.6 | 3,481.6 | 606.0 | 138.1 | 126.1 | 158.5 | 56.6 |
| Current Liabilities | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 504.2 | 443.8 | 426.7 | 762.6 | 881.5 | 298.8 | 354.0 | 222.7 | 228.6 | 29.9 | |
| Short-Term Debt | 52.4 | 55.5 | 39.5 | 74.8 | 70.6 | 62.6 | 0.0 | 2.2 | 2.1 | 2.1 | |
| Other Current Liabilities | 345.1 | 735.3 | 1,757.6 | 1,091.5 | 1,473.8 | 892.6 | 1,191.0 | 1,037.1 | 1,033.4 | 992.6 | |
| Current Liabilities | 1,850.8 | 1,534.5 | 2,523.2 | 2,528.5 | 2,427.3 | 1,607.5 | 2,070.5 | 1,807.2 | 1,819.0 | 1,550.9 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 219.3 | 214.7 | 379.6 | 176.2 | 171.6 | 231.0 | 68.9 | 54.2 | 50.3 | 26.7 | |
| Capital Leases | 219.4 | 254.2 | 188.8 | 36.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 37.8 | 42.4 | 0.0 | 6.2 | 66.7 | 0.3 | -166.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 3,167.5 | 3,118.6 | 2,760.4 | 3,223.5 | 3,937.1 | 946.8 | 304.2 | 386.0 | 422.9 | 358.1 |
| Long-Term Liabilities | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 217.2 | 237.5 | 214.7 | 206.8 | 219.3 | 407.7 | 2.4 | 0.0 | 0.0 | 0.0 | |
| Capital Leases | 0.0 | 246.8 | 254.2 | 243.7 | 219.4 | 236.3 | 188.8 | 199.7 | 203.6 | 207.7 | |
| Def. Tax Liability | 28.5 | 44.1 | 42.4 | 37.8 | 37.8 | 39.4 | 39.7 | 43.1 | 4.5 | 5.3 | |
| Total Liabilities | 3,132.5 | 2,255.8 | 3,118.6 | 3,294.5 | 3,165.6 | 2,290.7 | 2,760.4 | 2,340.4 | 2,319.1 | 1,813.7 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 248.7 | 248.6 | 248.6 | 248.6 | 246.3 | 246.3 | 232.3 | 193.3 | 166.8 | 3.3 | |
| Retained Earnings | 18,651.4 | 19,098.0 | 19,763.3 | 18,833.0 | 9,882.9 | -409.6 | -424.8 | -245.8 | -197.8 | -112.1 | |
| Comprehensive Income | -1,038.8 | -1,325.5 | 244.8 | 979.3 | 1,768.3 | 25.5 | 691.5 | 318.6 | -18.3 | 139.3 | |
| Total Common Equity | 19,083.5 | 19,411.1 | 20,245.9 | 20,055.6 | 11,893.7 | 1,371.8 | 493.5 | 266.2 | -49.3 | 30.5 |
| Total Common Equity | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 248.6 | 248.6 | 248.6 | 249.2 | 248.7 | 248.8 | 248.6 | 248.6 | 248.6 | 248.6 | |
| Retained Earnings | 18,295.6 | 18,682.2 | 19,098.0 | 18,883.2 | 18,651.4 | 19,466.2 | 19,763.3 | 19,305.4 | 19,144.8 | 19,335.2 | |
| Comprehensive Income | -1,478.8 | -1,443.4 | -1,325.5 | -1,340.0 | 194.1 | -947.6 | -984.6 | -904.8 | -902.5 | -858.8 | |
| Total Common Equity | 18,505.1 | 18,926.6 | 19,411.1 | 19,159.8 | 19,072.3 | 19,986.7 | 20,245.9 | 19,866.8 | 19,906.5 | 20,265.3 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 254.7 | 254.2 | 219.1 | 212.2 | 301.5 | 240.2 | 68.9 | 54.2 | 50.3 | 26.7 | |
| Book Value | 19,083.5 | 19,411.1 | 20,245.9 | 20,055.6 | 11,893.7 | 1,371.8 | 493.5 | 267.0 | -48.2 | 31.9 |
| Other | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 18,505.1 | 18,926.6 | 19,411.1 | 19,159.8 | 19,072.3 | 19,986.7 | 20,245.9 | 19,866.8 | 19,906.5 | 20,265.3 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -253.1 | -1,091.3 | -677.7 | 1,186.1 | 12,954.1 | 15,046.4 | -145.8 | -179.4 | -47.7 | -85.9 | |
| Depreciation & Amortization | 208.6 | 367.7 | 298.0 | 183.4 | 123.3 | 75.2 | 38.7 | 33.9 | 22.0 | 10.5 | |
| Stock-Based Compensation | 66.2 | 0.0 | 100.9 | 51.4 | 108.6 | 80.5 | 32.1 | 30.2 | 7.6 | 5.9 | |
| Change Working Capital | 2,442.7 | 516.6 | 1,220.6 | 5,574.8 | 4,518.5 | -10,730.4 | -93.1 | -83.4 | -41.0 | -8.0 | |
| Change In Accounts Receivable | 1,415.8 | 1,040.9 | 387.7 | 5,374.0 | 4,369.9 | -11,808.1 | -247.9 | 2.9 | -18.7 | -2.8 | |
| Change In Accounts Payable | 868.4 | -695.2 | 758.4 | 118.9 | 85.7 | 1,516.1 | 204.6 | -80.6 | -21.0 | -4.6 | |
| Change In Inventories | 108.8 | 170.9 | 74.5 | 81.9 | 62.9 | -438.4 | -49.8 | -5.8 | -1.3 | -0.6 | |
| Other Non-cash Items | -2,746.3 | 574.0 | -734.1 | -1,624.3 | -4,127.1 | 212.5 | 114.5 | 0.3 | -0.2 | -1.4 | |
| Cash from Operations | 2,987.3 | 0.0 | 0.0 | 5,371.4 | 13,577.4 | 889.7 | -13.5 | -198.5 | -58.2 | -52.6 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -302.1 | -33.5 | -438.5 | -437.6 | 276.8 | 217.6 | -869.6 | -342.0 | 663.2 | 227.4 | |
| Depreciation & Amortization | 163.3 | 145.1 | 57.9 | 45.0 | 176.4 | 48.8 | 53.7 | 41.6 | 78.8 | 41.3 | |
| Stock-Based Compensation | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 14.2 | 15.5 | |
| Change Working Capital | -215.3 | 730.4 | 570.1 | -438.4 | -745.4 | -722.9 | 2,554.2 | 241.5 | -803.8 | 639.4 | |
| Change In Accounts Receivable | 83.3 | 998.2 | -416.5 | 548.0 | -951.9 | -892.5 | 1,725.3 | 540.7 | -1,324.3 | 631.2 | |
| Change In Accounts Payable | -411.0 | -275.8 | 960.6 | -1,021.9 | 184.7 | 129.4 | 823.3 | -312.6 | 412.8 | -25.0 | |
| Change In Inventories | 112.4 | 8.0 | 26.0 | 35.6 | 21.9 | 40.2 | 5.7 | 13.3 | 58.0 | 33.2 | |
| Other Non-cash Items | 585.9 | -48.8 | -34.3 | 43.3 | -254.5 | -174.8 | 21.0 | -285.4 | -158.4 | -150.7 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 850.9 | 811.2 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -620.1 | -719.4 | -286.5 | -250.1 | -363.3 | -154.0 | -85.4 | -71.1 | -67.9 | -57.7 | |
| Acquisitions | -332.4 | 183.3 | 0.0 | -336.9 | 0.0 | -20.8 | -60.6 | -6.1 | 0.0 | 0.0 | |
| Investments | -11,805.7 | -10,971.7 | -12,370.3 | -7,128.4 | -47.8 | -394.7 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Sales of Investment | 6,362.9 | 9,136.8 | 10,740.2 | 1,216.3 | 375.2 | 26.5 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | -2,467.4 | 0.0 | 0.0 | -455.4 | 0.6 | -23.1 | 1.2 | 0.0 | 0.7 | 5.2 | |
| Cash from Investing | -6,464.0 | 0.0 | 0.0 | -6,954.5 | -35.3 | -566.1 | -144.8 | -77.1 | -67.1 | -52.5 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -63.4 | -69.1 | 567.9 | -650.5 | -100.5 | -90.9 | -151.9 | -148.6 | -190.2 | -151.2 | |
| Acquisitions | 255.5 | 0.2 | -2.2 | -82.1 | 0.8 | 0.3 | 0.2 | 0.0 | 4.3 | -336.9 | |
| Investments | -4,255.7 | -3,397.8 | -1,902.9 | -2,639.3 | -2,290.2 | -3,230.4 | -2,619.2 | -5,312.9 | -3,721.2 | -744.1 | |
| Sales of Investment | 1,436.9 | 2,470.8 | 1,932.7 | 4,684.1 | 3,039.2 | 3,158.3 | 2,522.1 | 2,960.4 | 1,183.5 | 97.2 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 28.5 | -97.2 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2,695.1 | -1,232.2 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -52.4 | 0.0 | 0.0 | -40.1 | -59.9 | -66.7 | -14.3 | -3.1 | -2.1 | -1.6 | |
| Debt Issued | 101.4 | 254.2 | 35.1 | 47.0 | -29.4 | 128.0 | 185.6 | 17.7 | 6.0 | 25.3 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 110.5 | 160.9 | 753.0 | 375.4 | 361.7 | 0.0 | |
| Repurchase of Common Stock | -302.5 | 0.0 | 0.0 | -738.5 | -986.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | -484.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.3 | 0.0 | 0.0 | 0.0 | 0.8 | 0.0 | 156.0 | 11.0 | 5.6 | 0.0 | |
| Cash from Financing | -354.8 | 0.0 | 0.0 | -778.6 | -1,419.3 | 94.2 | 894.7 | 383.3 | 365.2 | -1.6 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -12.1 | -9.3 | |
| Debt Issued | 0.0 | 269.6 | -23.4 | 38.8 | 10.5 | -11.0 | 18.2 | 17.4 | 29.3 | 5.5 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.8 | -301.7 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -12.9 | -311.0 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -3,792.1 | -931.2 | -1,901.8 | -2,211.4 | 12,182.4 | 482.5 | 691.1 | 107.7 | 239.4 | -131.6 | |
| Closing Cash Balance | 10,382.8 | 7,672.1 | 9,761.9 | 11,663.7 | 13,875.1 | 1,692.7 | 1,210.2 | 519.1 | 411.5 | 172.1 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -2,421.2 | -195.7 | 1,053.1 | 893.3 | -633.1 | -379.7 | 1,426.5 | -3,189.6 | -1,832.1 | -670.8 | |
| Closing Cash Balance | 7,672.1 | 11,859.2 | 12,054.9 | 11,001.7 | 10,108.4 | 10,741.5 | 11,121.2 | 9,694.7 | 11,663.7 | 13,495.8 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 2,367.2 | 269.8 | -244.6 | 4,665.9 | 13,214.1 | 735.7 | -98.9 | -269.6 | -126.0 | -110.3 | |
| Real Free Cash Flow | 2,301.0 | 269.8 | -345.5 | 4,614.5 | 13,105.5 | 655.2 | -131.1 | -299.9 | -133.7 | -116.2 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 237.7 | 811.1 | 700.0 | -1,472.2 | -601.7 | -778.7 | 1,607.4 | -493.0 | 660.7 | 660.0 | |
| Real Free Cash Flow | 237.7 | 811.1 | 700.0 | -1,472.2 | -601.7 | -778.7 | 1,607.4 | -493.0 | 646.5 | 644.5 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | -19.3 | 57.1 | -1.4 |
| P/S | 7.6 | 27.3 | 9.4 |
| P/B | 1.2 | 8 | 5.2 |
| P/FCF | 79.1 | -24.3 | -1.5 |
| Market cap | $25.3 | $25.4 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 0 % | 3.2 % | 0 % |
| Debt to Income | -23.8 % | -12.2 % | 0 % |
| Debt to Free cash flow | 97.5 % | 1008.5 % | 0 % |
| Interest expense percentage | -1.2 % | -1.6 % | 44.7 % |
| Current ratio | 8.6 | 5.4 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | -6.1 % | 13.6 % | 0 % |
| ROA | -5.2 % | 11.2 % | 0 % |
| CapEx to Revenue | 8 % | 20.7 % | 0 % |
| RaD to Revenue | 0 % | 79.7 % | 0 % |
| ROEM | 422,532.6 | 1361810.2 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 82.5 % | 15.7 % | 68.7 % |
| Operating margin | -29.6 % | -18.2 % | 35.5 % |
| Net margin | -18.1 % | -22.7 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0.2 % | 0 % |
| Dividend payout percentage | 0 % | 0.8 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 239.2 mil | 241.5 mil |
| Employee count | 6.8 tis | 4.0 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
